ROSEN, a top-tier law firm, Dentsply Sirona Inc. Investing.com encourages investors who have lost more than $100,000 to secure advice before it's needed, on Jan. 27 in the Securities section.

Spread the love

NEW YORK, NY–(The News File Corporation – January 19, 2025) – why: Rosen Law Firm, a global investor rights law firm, is recalling Dentsply Sirona Inc. (NASDAQ: XRAY ) common stock to purchasers between May 6, 2021 and November 6, 2024, both dates inclusive (the “Class Period”). Important January 27, 2025 Plaintiff’s Lead Deadline.

So what? If you purchase Dentsply Sirona common stock during the Class Period, you may receive compensation without paying any out-of-pocket fees or expenses through a contingent payment arrangement.

What to do next: To join the Dentsply Sirona class action, go to or call Philip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you want to serve as lead plaintiff, you must move the court Not later than January 27, 2025. A lead plaintiff is a representative party who conducts litigation on behalf of other class members.

Why the Rose Rule? We encourage investors to select a qualified advisor with a track record of success in a leadership role. Oftentimes, the organizations that issue the ads don’t have comparable experience, resources, or any meaningful peer recognition. Most of these firms do not litigate securities class actions but are brokers who refer clients or work in partnership with law firms. Be wise when choosing advice. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class actions and shareholder derivative litigation. Rosen Law Firm brought the largest securities class action against a Chinese company at the time. Rosen Law Firm is rated Class 1 by ISS Securities. Action (WA:) Services in 2017 for the securities division of the action settlement number. The firm has been ranked in the top 4 every year since 2013 and has returned hundreds of millions of dollars to investors. In the year In 2019 alone, the company raised over $438 million for investors. In the year In 2020, founding partner Lawrence Rosen was named a Titan of the Plaintiffs Bar by Law360. Many of the firm’s lawyers are accredited by Laudragon and Super Lawyers.

Details of the case:- According to the lawsuit, during the class period, the defendants made false and/or misleading statements and/or failed to disclose material facts necessary to support the statements, which, in light of the circumstances of the statements, were not false or misleading. In fact, bite aligners have been causing serious harm to patients since at least May 2021, according to backlogged injury reports, and Densply Sirona filed a lawsuit against the US Food and Drug Administration (“FDA”) in 2024. The problem is that customer service staff and dentists overseeing other patients with dental problems have made them ineligible for BITE treatment. As a result, Defendants’ Byte customer experience, and the extensive network of dentists who supervise and control the treatment of each customer, are materially misleading and/or lack a reasonable basis. In addition, Dentsply Sirona hid that the high conversion rate was due to the sales incentive to register the prohibited patients. The lawsuit alleges investors were harmed when real listings entered the market.

To join the Dentsply Sirona class action, go to or call Philip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for class action information.

No class confirmed. Unless a class is confirmed, it will not be represented by advice unless you own one. You can choose the advice of your choice. You can also remain a member of a class you are not in and do nothing at this point. An investor’s ability to participate in any future recovery is not dependent on serving as the lead plaintiff.

Notice of attorney. Previous results do not guarantee the same results.

————————————-

To view the source of this press release, please visit https://www.newsfilecorp.com/release/237618.